Business Description
Glycorex Transplantation AB
ISIN : SE0000524530
Share Class Description:
NGM:GTAB B: Class BTotal Employee Number:
20Compare
Compare
Traded in other countries / regions
GTAB B.SwedenO33.Germany IPO Date
1999-12-28Description
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.12 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -68.81 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.09 | |||||
Beneish M-Score | -3.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.5 | |||||
3-Year EBITDA Growth Rate | 81.7 | |||||
3-Year EPS without NRI Growth Rate | 6.2 | |||||
3-Year Book Growth Rate | -24.2 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 16.78 | |||||
9-Day RSI | 26.81 | |||||
14-Day RSI | 34.87 | |||||
3-1 Month Momentum % | 42.62 | |||||
6-1 Month Momentum % | 12.26 | |||||
12-1 Month Momentum % | -18.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.54 | |||||
Quick Ratio | 1.16 | |||||
Cash Ratio | 0.56 | |||||
Days Inventory | 257.63 | |||||
Days Sales Outstanding | 64.46 | |||||
Days Payable | 59.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | 1.18 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.12 | |||||
Operating Margin % | -24.41 | |||||
Net Margin % | -25.29 | |||||
EBITDA Margin % | -0.26 | |||||
FCF Margin % | -0.1 | |||||
OCF Margin % | -0.04 | |||||
ROE % | -26.21 | |||||
ROA % | -18.35 | |||||
ROIC % | -22.28 | |||||
3-Year ROIIC % | -5.94 | |||||
ROC (Joel Greenblatt) % | -64.14 | |||||
ROCE % | -23.51 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.99 | |||||
PB Ratio | 3.71 | |||||
Price-to-Tangible-Book | 7.3 | |||||
EV-to-EBIT | -12 | |||||
EV-to-EBITDA | -1132.2 | |||||
EV-to-Revenue | 2.93 | |||||
EV-to-FCF | -3355.66 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Median-PS-Value | 0.49 | |||||
| Price-to-Net-Current-Asset-Value | 29.2 | |||||
Earnings Yield (Greenblatt) % | -8.33 | |||||
FCF Yield % | -0.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Glycorex Transplantation AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 37.881 | ||
| EPS (TTM) (kr) | -0.11 | ||
| Beta | 1.4372 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 44.26 | ||
| 14-Day RSI | 34.87 | ||
| 14-Day ATR (kr) | 0.123089 | ||
| 20-Day SMA (kr) | 1.64575 | ||
| 12-1 Month Momentum % | -18.69 | ||
| 52-Week Range (kr) | 1.04 - 2.75 | ||
| Shares Outstanding (Mil) | 78.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Glycorex Transplantation AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Glycorex Transplantation AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-27 | In 114 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 23 days | ||
| General meeting for 2025 | 2026-06-04 17:30 | 1.68 (+11.26%) | ||
| First quarter earnings results for 2026 | 2026-05-22 | 1.21 (-0.41%) | ||
| Annual report for 2025 | 2026-04-30 | 1.21 (+7.08%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 1.42 (+3.28%) | ||
| Third quarter earnings results for 2025 | 2025-11-28 | 1.58 (+2.60%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 2.17 (-1.36%) | ||
| General meeting for 2024 | 2025-05-26 | 2.20 (-6.38%) | ||
| First quarter earnings results for 2025 | 2025-05-23 | 2.27 (+7.08%) |
Show
Entries
Glycorex Transplantation AB Frequently Asked Questions
What is Glycorex Transplantation AB(NGM:GTAB B)'s stock price today?
The current price of NGM:GTAB B is kr1.46. The 52 week high of NGM:GTAB B is kr2.75 and 52 week low is kr1.04.
When is next earnings date of Glycorex Transplantation AB(NGM:GTAB B)?
The next earnings date of Glycorex Transplantation AB(NGM:GTAB B) is 2026-08-28.
Does Glycorex Transplantation AB(NGM:GTAB B) pay dividends? If so, how much?
Glycorex Transplantation AB(NGM:GTAB B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Glycorex Transplantation AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers